RU2803098C1 - Application of fungicides to combat apple mosaic virus - Google Patents

Abstract

FIELD: agriculture.

SUBSTANCE: invention relates to fungicidal plant protection products. To combat the causative agent of the disease of apple trees Venturia inaequalis, a fungicidal composition containing fluopyram and fosetil aluminium is used, which is applied at the stages of release of ascospores and the stage of plant development starting from ВВСН 55 to ВВСН 75 at a consumption rate of 0.1 to 1.5 kg/ha/mCH.

EFFECT: reduced amount of Venturia inequalis inoculum capable of infecting a plant or parts of an apple plant in the next season.

4 cl, 8 tbl, 4 ex

Description

The present invention relates to the use of compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, to combat mosaic rot of apple trees, to a method of treating apple tree plants or parts of apple tree plants for combating mosaic rot, and methods for combating mosaic rot of plants and plant parts, in particular leaves, by treating them with compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum.

State of the art

Venturia inaequalis, a semi-biotrophic fungus, is the causative agent of apple scab disease in apple plants and parts across a wide geographic range of all apple growing areas (Bowen JK, et al. 2011. Venturia inaequalis: the causal agent of apple scab. Molecular Plant Pathology 12: 105- 122). Venturia inaequalis has received considerable attention because its already very low incidence can result in unmarketable fruit, which will have important economic consequences.

Apple mosaic rot is a specific form of apple scab caused by Venturia inaequalis. Symptoms of mosaic rot develop as small, scattered light to dark gray sporulating lesions on the abaxial surface of the leaf. In the literature, diffuse scab patterns occurring on both adaxial and abaxial surfaces are referred to as “leaf scab.” Mosaic rot, however, refers only to the abaxial side and expresses a type of lesion different from the classic symptoms of ascospores or conidial scabs. Typical symptoms of mosaic rot begin to appear on the side of the leaf blade, often limited to only one half of the blade. Their development is a consequence of primary infections with ascospores and/or subsequent secondary conidial infections, which develop into the classic diffuse scab on the abaxial surface of the leaves. Mosaic rot is not found on fruits, unlike classic apple scab. Symptoms of mosaic rot appear two to three months after the appearance of the first classic sporulating scab lesions of primary infections and one to two months after the first secondary infections on senescent leaves, that is, on the leaves of rosettes and shoots (leaves of flower clusters) and the leaves of prolongation shoots covering base of shoots. During this period, the fungus is inhibited rather than killed before ontogenic resistance breaks down (Gessler and Stumm 1984; Valsangiacomo and Gessler 1988), and increased susceptibility to diseases of mature leaves reappears, accompanied by the appearance of mosaic rot symptoms on these mature leaves in late summer (Olivier 1984). Symptoms of mosaic rot progress throughout the season along the extension shoot towards senescent leaves towards the tip of the extension shoot, which develops later than the basal leaves. Mosaic blight can pose a significant risk to apple growers because late infection and fungal growth on shoot leaves late in the season can result in a significant increase in the amount of apple scab inoculum in fallen apple leaves. Overwintered spores may contribute to increased ascospore distribution the following spring, resulting in higher infection pressure and apple scab incidence the following season. This may increase the need for more crop protection chemicals.

According to various studies, several factors influence the development of apple scab symptoms on older leaves. Among the high density of leaf hairs on the abaxial surface of apple leaves, changes in other ontogenic resistance factors are important for the development of mosaic rot. These include chemical compounds such as salicylic acid (Hugot et al. 1999; Kus et al. 2002), pathogenesis-related proteins (Hugot et al. 1999; Wyatt et al. 1991), phenolic compounds (Mikulic Petkovšek et al. 2008) physiological barriers such as the cuticle (Ficke et al. 2002, 2003; Peries 1962), restricted phloem movement (Gacia-Ruiz and Murphy 2001) or limiting nutrient substrate for fungal infection (Jeun and Hwang 1991). Changes in these factors may influence the infection process of V. inaequalis during hyphal growth and stroma formation and may contribute to the development of mosaic rot symptoms on the abaxial epidermis of leaves (Li and Xu 2002).

Succinate dehydrogenase inhibitors (SDHI) are active ingredients that inhibit fungal succinate dehydrogenase, an essential enzyme in the respiratory chain. There are different classes of SDHI, and some commercial products sold as fungicides contain SDHI.

Fluopyram refers to a compound of general formula (I)

also known as N-{2-[3-chloro-5-(trifluoromethyl)-2-pyridyl]ethyl}-α,α,α-trifluoro-orthotoluamide or N-[2-[3-chloro-5-(trifluoromethyl )-2-pyridinyl]ethyl]-2-(trifluoromethyl)benzamide. Fluopyram is widely known as a fungicide belonging to the group of succinate dehydrogenase (SDH) inhibitors. WO 2004/016088 discloses pyridinylethylbenzamide fungicide derivatives, eg fluopyram, against various phytopathogenic fungi. However, it is not apparent from the publication disclosure that fluopyram is very effective against the mosaic rot described above. More specifically, the suitability of fluopyram in combination with fosetyl aluminum for the treatment of mosaic rot of apple trees has not been clearly disclosed.

Phosphonates are salts or esters of phosphorous acid. Salts of phosphorous acid are phosphites. The phosphites may be potassium phosphite, monobasic sodium phosphite, dibasic sodium phosphite, or ammonium phosphite. Phosphites can also be mixtures of various salts, such as those sold as the product Phostrol (Nufarm, USA). In one example, phosphoric acid is mixed with potassium hydroxide to provide potassium phosphite. Phosphorous esters are ethyl hydrophosphonates, either as an aluminum salt forming aluminum tris(O-ethyl)phosphonate, also called aluminum ethoxyphosphinate, or sodium ethoxyphosphinate, or calcium ethoxyphosphinate. Phosphonates are known to have fungicidal activity, in particular against oomycetes such as Phytophthora, Plasmopara, Pythium, as well as others such as Ascomycetes ((Penn State, College of Agricultural Science, Center for Turfgrass Science http://plantscience.psu .edu/research/centers/turf/extension/factsheets/phosphonate-products and Petré, R.et al., 2015, Acta Hort. (ISHS) 1094:431-438))

Fosetyl aluminum refers to a compound of general formula (II)

Also known as aluminum methylhydrogenphosphonate (CAS-No 39148-24-8). Phosetyl aluminum was described in DE2456627 as a systemic and therapeutic fungicide with high activity against oomycetes. Fosetyl aluminum has also been described as a plant defense inducer in several plants (Petré, R. et al., 2015, Acta Hort. (ISHS) 1094:431-438).

Fungicidal compositions containing fluopyram and fosetyl aluminum are described in EP-A 1 713 334. However, from the disclosure of this publication it is not obvious that fungicidal compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group phosphonates, particularly fosetyl aluminum, are highly effective against mosaic rot in apple trees, as described above.

The essence of the invention

Surprisingly, it has been found that compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, are excellent for controlling mosaic rot in apple trees.

In one embodiment, compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, particularly fluopyram, and a fungicide selected from the group of phosphonates, particularly fosetyl aluminum, are excellent for reducing Venturia inequalis inoculum in wilting leaves at the BBCH 71 developmental stage and beyond.

According to one embodiment, the use of compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, is disclosed for the control of mosaic leaf rot.

According to one embodiment, a method of treating plants or plant parts to combat mosaic leaf rot by treating them with a composition containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum.

According to one embodiment, a method is disclosed for treating plants or plant parts to reduce the inoculum of Venturia inequalis in wilting leaves at the BBCH development stage in the range of BBCH 71 to 97 and later by treating them with a composition containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum.

Definitions

Mosaic rot (also referred to as leaf scab) refers to a specific form of disease caused by Venturia inaequalis, visible on mature shoot leaves and rosette leaves of apple plants or trees at the development stage BBCH for pome fruits from 69 to 97, culminating at BBCH from 72 to 97, preferably on BBCH 91 to 97.

Mosaic rot may be caused by a different developmental stage of Venturia inequalis, hitherto unknown in the typical apple scab disease cycle. Classic apple scab occurs in the spring at the pre-flowering stage (BBCH stage 5: inflorescence emergence) and continues until harvest and even during storage of pome fruits. In contrast, mosaic rot occurs only on leaves that have begun senescence, typically at stage BCCH 71. Senescent leaves drop off and contain even more inoculum of both classic apple scab and mosaic rot. Mosaic rot may be based on a mutation or specific strains that are still under scientific research. Mosaic rot may be characterized by more superficial mycelial development and fewer conidiophores compared to classic apple scab. Mosaic rot may also be characterized by symptoms such as necrotic tissue on rosette leaves, which are the leaves of flower clusters and the leaves of shoots of fruiting twigs and extension shoots. Using specific microscopic techniques, Venturia inequalis mosaic blight hyphae have been shown to become more superficial on the cuticle compared to classic apple scab, which is primarily present below the cuticle.

Venturia inaequalis with mosaic rot symptoms may also be characterized by its ability to grow saprophytically compared to Venturia inaequalis of classic apple scab. One method of testing the ability to grow more saprophically is to visually inspect the fungus growing on individual leaves or on artificial substrates. Mosaic rot can also be characterized by microscopic methods to determine the number of necrotic cells in the tissue of the infected leaf, which will be higher than with classic apple scab.

In the context of the present invention, “control of mosaic rot of apple trees” means a significant reduction in the infestation of the specific form of Venturia inaequalis present with the symptoms of mosaic rot, compared to an untreated plant, preferably a significant reduction (40-75%) compared to an untreated plant (100% ), more preferably an even greater reduction (60-79%) compared to the untreated plant (100%); even more preferably, mosaic rot infestation is completely suppressed (70-100%). Wrestling can be therapeutic, i.e. for the treatment of already infected plants, or protective, for the protection of plants that have not yet been infected.

In the context of the present invention, "reducing the inoculum of Venturia inequalis in wilting leaves from development stage BBCH 71 and later on fallen leaves on the soil" means a significant reduction in the inoculum of Venturia inequalis in wilting leaves from development stage BBCH 71 and later compared to an untreated plant, preferably a significant reduction (40%) compared to the untreated plant (100%), more preferably a significant reduction (60%) compared to the untreated plant (100%); even more preferably, the inoculum of Venturia inequalis in wilting leaves at development stage BBCH 71 and later is completely suppressed (70-100%). Determination of the inoculum can be done by quantitative polymerase chain reaction (qPCR) using primers specific for mosaic blight. The development of mosaic blight can occur at an exponential rate between growth stages BBCH 71 and 91. Control can be curative, that is, to treat already infected plants, or protective, to protect plants that have not yet been infected.

In the context of the present invention, a plant is preferably understood to mean a plant at the dormant stage (BBCH 00 in accordance with the monograph BBCH of the German Federal Biological Research Center for Agriculture and Forestry, 2nd edition, 2001) or after the end of leaf fall (BBCH 97). All BBCH numbers presented refer to the BBCH definition for pome fruits.

Treatment can be carried out preferably at BBCH 69 plus two weeks. This is an alternative way of describing the time of application: the period of time between 69 (all petals have fallen) and the beginning of fruit development is a very long period. Since the point in time when all the petals have fallen can be determined quite easily, the expression "BBCH plus two weeks" provides a practical explanation regarding the timing of application.

All plants and plant parts can be processed in accordance with the present invention.

By plants, as used herein, we mean all plants and plant populations, such as desirable and undesired wild plants or crop plants (including naturally occurring crop plants). Agricultural plants can be plants that can be obtained by conventional methods of selection and optimization or by biotechnological and genetic engineering methods or combinations of these methods, including transgenic plants and including plant varieties that are and are not protected by plant breeders' rights.

The term "apple tree" means any plant or part of a plant of the genus Malus, in particular cultivated Malus pumila or Malus domesticus. The definition includes any Malus variety, such as apples to be cooked, cider apples, and direct consumption varieties such as Ambrosia, Fuji, Gala, Golden Delicious, Granny Smith, Honeycrisp, Jonagold, McIntosh, Pink Lady, Red Delicious, or wild Malus species such as Malus sieversii or Malus sylvestris (wild apple). The term "apple tree" refers not only to the fruit, but to the entire deciduous tree or any part of it, particularly the leaves and shoots.

The term "plant parts" should be understood to mean all above-ground and underground parts and organs of plants, such as shoot, leaf, flower and root, for example, ears, leaves, needles, pedicels, stems, trunks, flowers, fruiting bodies, fruits, seeds (including seeds of transgenic plants), seedlings, rhizomes, grafted seedlings and cuttings, as well as roots and rhizomes. Plant parts also include harvested materials, as well as materials for vegetative and generative propagation, such as roots, cuttings, grafted seedlings, rhizomes, mucilages and seedlings. The leaves may be rosette leaves, shoots or shoots.

Preferred parts of the plant are leaves, shoots, rosette leaves, shoots or shoots are very preferred, leaves of shoots are especially preferred.

Succinate dehydrogenase inhibitors (SDHI) are active ingredients that inhibit fungal succinate dehydrogenase, an essential enzyme in the respiratory chain.

In one embodiment, the SDHIs are selected from the group consisting of benzovindiflupyr (1072957-71-1), bixafen (581809-46-3), boscalid (188425-85-6), fluindapyr (1383809-87-7), fluopyram (658066 -35-4), (2.8) fluxapyroxad (907204-31-3), isofetamide (875915-78-9), isoflucipram (1255734-28-1), isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti -epimeric racemate 1RS,4SR,9SR) (881685-58-1), isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), isopyrazam (anti-epimeric enantiomer 1R,4S,9S), isopyrazam (anti-epimeric enantiomer 1S ,4R,9R), isopyrazam (syn-epimeric racemate 1RS,4SR,9RS), isopyrazam (syn-epimeric enantiomer 1R,4S,9R), isopyrazam (syn-epimeric enantiomer 1S,4R,9S), penthiopyrad (183675-82 -3), pidiflumetofen (1228284-64-7).

Cas numbers are given in parentheses.

In one embodiment, the SDHIs are selected from the group consisting of benzovindiflupyr (1072957-71-1), bixafen (581809-46-3), boscalid (188425-85-6), fluindapyr (1383809-87-7), fluopyram (658066 -35-4), (2.8) fluxapyroxad (907204-31-3), isofetamide (875915-78-9), isoflucipram (1255734-28-1), isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti -epimeric racemate 1RS,4SR,9SR) (881685-58-1), isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), isopyrazam (anti-epimeric enantiomer 1R,4S,9S), isopyrazam (anti-epimeric enantiomer 1S ,4R,9R), isopyrazam (syn-epimeric racemate 1RS,4SR,9RS), isopyrazam (syn-epimeric enantiomer 1R,4S,9R), isopyrazam (syn-epimeric enantiomer 1S,4R,9S), penthiopyrad (183675-82 -3), pidiflumetofen (1228284-64-7).

In one embodiment, the SDHIs are selected from the group consisting of benzovindiflupyr (1072957-71-1), bixafen (581809-46-3), boscalid (188425-85-6), fluopyram (658066-35-4), (2.8) fluxapyroxade (907204-31-3), isoflucipram (1255734-28-1), isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) (881685-58-1), isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), isopyrazam (anti-epimeric enantiomer 1R,4S,9S), isopyrazam (anti-epimeric enantiomer 1S,4R,9R), isopyrazam (syn-epimeric racemate 1RS,4SR,9RS) , isopyrazam (syn-epimeric enantiomer 1R,4S,9R), isopyrazam (syn-epimeric enantiomer 1S,4R,9S), penthiopyrad (183675-82-3), pidiflumetofen (1228284-64-7).

In one embodiment, the SDHIs are selected from the group consisting of benzovindiflupyr (1072957-71-1), bixafen (581809-46-3), boscalid (188425-85-6), fluopyram (658066-35-4), (2.8) fluxapyroxade (907204-31-3), isoflucipram (1255734-28-1), penthiopyrad (183675-82-3), pidiflumetofen (1228284-64-7).

In one embodiment, fluopyram is preferred.

The phosphonates are selected from the group consisting of potassium phosphite, monobasic sodium phosphite, dibasic sodium phosphite, ammonium phosphite, ethyl aluminum hydrogen phosphate, sodium ethyl hydrogen phosphonate, and calcium ethyl hydrogen phosphonate.

In one embodiment, the phosphonates are selected from the group consisting of potassium phosphite, monobasic sodium phosphite, dibasic sodium phosphite, ammonium phosphite, aluminum ethyl hydrogen phosphates.

In one embodiment, the phosphonates are selected from the group consisting of potassium phosphite, monobasic sodium phosphite, dibasic sodium phosphite, ammonium phosphite, and mixtures thereof.

In one embodiment, the phosphonates are selected from the group consisting of aluminum ethyl hydrogen phosphates, also known as fosetyl aluminum.

Detailed description of the invention

In one embodiment, the use of mosaic blight control compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates is disclosed on leaves at BBCH stages 71 to 97.

According to one embodiment, the use of mosaic blight control compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates is disclosed on a rosette of leaves at BBCH development stages 71 to 97.

In one embodiment, the use of mosaic blight control compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates is disclosed on the leaves of shoots at fruit stages BBCH 71 to 97.

In one embodiment, the use of mosaic blight control compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates is disclosed on the leaves of shoots at BBCH fruit stages 71 to 97.

In one embodiment, the use of compositions for reducing the inoculum of Venturia inequalis in wilting leaves containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates on leaves at BBCH development stages 71 to 97 is disclosed.

In one embodiment, the use of compositions for reducing inoculum of Venturia inequalis in wilting leaves containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates on a rosette of leaves at BBCH developmental stages 71 to 97 is disclosed.

In one embodiment, the use of compositions for reducing the inoculum of Venturia inequalis in wilting leaves, containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates, on the leaves of shoots at BBCH fruit stages 71 to 97 is disclosed.

In one embodiment, the use of compositions for reducing the inoculum of Venturia inequalis in wilting leaves, containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates, on the leaves of shoots at BBCH fruit stages 71 to 97 is disclosed.

In one embodiment, the use of mosaic blight control compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates is disclosed on leaves at the BBCH stage of development from 69 plus two weeks to 97.

According to one embodiment, the use of mosaic blight control compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates is disclosed on a rosette of leaves at the BBCH stage of development from 69 plus two weeks to 97.

According to one embodiment, the use of mosaic rot control compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates is disclosed on the leaves of shoots at the BBCH fruit stage of 69 plus two weeks to 97.

According to one embodiment, the use of mosaic blight control compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates is disclosed on the leaves of shoots at the BBCH fruit stage of 69 plus two weeks to 97.

In one embodiment, the use of compositions for reducing the inoculum of Venturia inequalis in wilting leaves, containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates, is disclosed on leaves at the BBCH stage of development from 71 to 69 plus two weeks.

According to one embodiment, the use of compositions for reducing the inoculum of Venturia inequalis in wilting leaves containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates on a rosette of leaves at the BBCH stage of development from 69 plus two weeks to 97 is disclosed.

In one embodiment, the use of compositions for reducing inoculum of Venturia inequalis in wilting leaves, containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates, is disclosed on the leaves of shoots at the BBCH fruit stage of 69 plus two weeks to 97.

In one embodiment, the use of compositions for reducing the inoculum of Venturia inequalis in wilting leaves, containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates, is disclosed on the leaves of shoots at the BBCH fruit stage of 69 plus two weeks to 97.

List 1 shows a combination of two active ingredients of compositions for combating mosaic rot, containing a fungicide selected from the group of succinate dehydrogenase inhibitors and a fungicide selected from the group of phosphonates:

List 1:

benzovindiflupyr + sodium phosphite, bixafen + sodium phosphite, boscalid + sodium phosphite, fluindapir + sodium phosphite, fluopyram + sodium phosphite, fluxapyroxad + sodium phosphite, isofetamide + sodium phosphite, isofetamide + sodium phosphite, isopyrazam (mixture of syn-epimeric racemate 1RS,4SR ,9RS and anti-epimeric racemate 1RS,4SR,9SR) + sodium phosphite, isopyrazame (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) + sodium phosphite, isopyrazame (anti-epimeric racemate 1RS,4SR,9SR) + sodium phosphite, isopyrazame (anti-epimeric enantiomer 1R,4S,9S) + sodium phosphite, isopyrazame (syn-epimeric enantiomer 1R,4S,9R), + sodium phosphite, isopyrazame (syn-epimeric enantiomer 1S) ,4R,9S) + sodium phosphite, penthiopyrad + sodium phosphite, pidiflumetofen + sodium phosphite, benzovindiflupyr + monobasic potassium phosphite, bixaphen + monobasic potassium phosphite, boscalid + monobasic potassium phosphite, fluindapyr + monobasic potassium phosphite, fluopyram + monobasic potassium phosphite lia, fluxapyroxad + monobasic potassium phosphite, isophetamide + monobasic potassium phosphite, isophetamide + monobasic potassium phosphite, isopyrazame (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) + monobasic potassium phosphite, isopyrazame (mixture of syn- epimer racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) + monobasic potassium phosphite, isopyrazame (anti-epimeric racemate 1RS,4SR,9SR) + monobasic potassium phosphite, isopyrazame (anti-epimeric enantiomer 1R,4S, 9S) + monobasic potassium phosphite, isopyrazame (syn-epimeric enantiomer 1R,4S,9R), + monobasic potassium phosphite, isopyrazame (syn-epimeric enantiomer 1S,4R,9S) + monobasic potassium phosphite, pentiopyrad + monobasic potassium phosphite, pidiflumetofen + monobasic potassium phosphite, benzovindiflupyr + dibasic potassium phosphite, bixaphen + dibasic potassium phosphite, boscalid + dibasic potassium phosphite, fluindapyr + dibasic potassium phosphite, fluopyram + dibasic potassium phosphite, fluxapyroxad + dibasic potassium phosphite, isofetamide + dibasic potassium phosphite potassium osphite, isophetamide + dibasic phosphite potassium, isopyrazame (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) + dibasic potassium phosphite, isopyrazame (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR ,9SR) + dibasic potassium phosphite, isopyrazame (anti-epimeric racemate 1RS,4SR,9SR) + dibasic potassium phosphite, isopyrazame (anti-epimeric enantiomer 1R,4S,9S) + dibasic potassium phosphite, isopyrazame (syn-epimeric enantiomer 1R, 4S,9R), + dibasic potassium phosphite, isopyrazam (syn-epimeric enantiomer 1S,4R,9S) + dibasic potassium phosphite, penthiopyrad + dibasic potassium phosphite, pidiflumetofen + dibasic potassium phosphite, benzovindiflupyr + ammonium phosphite, bixaphen + ammonium phosphite, boscalid + ammonium phosphite, fluindapyr + ammonium phosphite, fluopyram + ammonium phosphite, fluxapyroxad + ammonium phosphite, isofetamide + ammonium phosphite, isofetamide + ammonium phosphite, isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric ra cemate 1RS,4SR, 9SR) + ammonium phosphite, isopyrazame (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) + ammonium phosphite, isopyrazame (anti-epimeric racemate 1RS,4SR,9SR) + ammonium phosphite, isopyrazame (anti-epimeric enantiomer 1R,4S,9S) + ammonium phosphite, isopyrazame (syn-epimeric enantiomer 1R,4S,9R), + ammonium phosphite, isopyrazame (syn-epimeric enantiomer 1S,4R,9S) + ammonium phosphite, penthiopyrad + ammonium phosphite, pidiflumetofen + ammonium phosphite, benzovindiflupyr + fosetyl ammonium, bixafen + fosetyl ammonium, boscalid + fosetyl ammonium, fluindapir + fosetyl ammonium, fluopyram + fosetyl ammonium, fluxapyroxad + fosetyl ammonium, isofetamide + f osetil-ammonium, isofetamide + fosetyl ammonium, isopyrazame (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) + fosetyl ammonium, isopyrazame (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) + fosetyl ammonium, isopyrazam (anti-epimeric racemate 1RS,4SR,9SR) + fosetyl ammonium, isopyrazam (anti-epimeric enantiomer 1R,4S,9S) + fosetyl ammonium, isopyrazam (syn- epimeric enantiomer 1R,4S,9R), + fosetyl ammonium, isopyrazam (syn-epimeric enantiomer 1S,4R,9S) + fosetyl ammonium, penthiopyrad + fosetyl ammonium, pidiflumetofen + fosetyl ammonium, benzovindiflupyr + sodium ethyl hydrophosphonate, bixaphen + sodium ethylhydrogenphosphonate, boscalid + sodium ethylhydrogenphosphonate, fluindapir + sodium ethylhydrogenphosphonate, fluopyram + sodium ethylhydrogenphosphonate, fluxapyroxad + sodium ethylhydrogenphosphonate, isofetamide + sodium ethylhydrogenphosphonate, isofetamide + sodium ethylhydrogenphosphonate, isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti- epimeric racemate + sodium ethylhydrogenphosphonate, isopyrazam (anti-epimeric enantiomer 1R,4S,9S) + sodium ethylhydrogenphosphonate, isopyrazame (syn-epimeric enantiomer 1R,4S,9R), + sodium ethylhydrogenphosphonate, isopyrazame (syn-epimeric enantiomer 1S,4R,9S) + ethylhydrogenphosphonate sodium, penthiopyrad + sodium ethylhydrogenphosphonate, pidiflumetofen + sodium ethylhydrogenphosphonate, benzovindiflupir + calcium ethylhydrogenphosphonate, bixafen + calcium ethylhydrogenphosphonate, boscalid + calcium ethylhydrogenphosphonate, fluindapir + calcium ethylhydrogenphosphonate, fluopyram + calcium ethylhydrogenphosphonate, fluxapyroxad + calcium ethylhydrogenphosphonate, isofetamide + eti calcium lhydrogenphosphonate, isofetamide + ethylhydrogenphosphonate calcium, isopyrazame (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR) + calcium ethyl hydrophosphonate, isopyrazame (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR, 9SR) + calcium ethylhydrogenphosphonate, isopyrazame (anti-epimeric racemate 1RS,4SR,9SR) + calcium ethylhydrogenphosphonate, isopyrazame (anti-epimeric enantiomer 1R,4S,9S) + calcium ethylhydrogenphosphonate, isopyrazame (syn-epimeric enantiomer 1R,4S,9R) , + calcium ethylhydrogenphosphonate, isopyrazam (syn-epimeric enantiomer 1S,4R,9S) + calcium ethylhydrogenphosphonate, penthiopyrad + calcium ethylhydrogenphosphonate, pidiflumetofen + calcium ethylhydrogenphosphonate.

In one embodiment, the use of mosaic blight control compositions containing any combination as disclosed in Listing 1 is disclosed on leaves at BBCH stages 71 to 97.

According to one embodiment, the use of mosaic blight control compositions containing any combination as disclosed in Listing 1 is disclosed on a rosette of leaves at BBCH stages 71 to 97.

In one embodiment, the use of mosaic blight control compositions containing any combination as disclosed in Listing 1 is disclosed on the leaves of shoots at fruit stages BBCH 71 to 97.

In one embodiment, the use of mosaic blight control compositions containing any combination as disclosed in Listing 1 is disclosed on the leaves of shoots at fruit stages BBCH 71 to 97.

In one embodiment, the use of mosaic blight control compositions containing fluopyram and fosetyl aluminum on leaves at BBCH stages 71 to 97 is disclosed.

In one embodiment, the use of fluopyram and fosetyl aluminum-containing mosaic blight control compositions on rosette leaves at BBCH stages 71 to 97 is disclosed.

In one embodiment, the use of fluopyram and fosetyl aluminum-containing mosaic blight control compositions on shoot leaves at BBCH fruit stages 71 to 97 is disclosed.

In one embodiment, the use of fluopyram and fosetyl aluminum-containing mosaic blight control compositions on shoot leaves at BBCH fruit stages 71 to 97 is disclosed.

In one embodiment, the use of Venturia inequalis inoculum reducing compositions containing any combination as disclosed in List 1 is disclosed on leaves at BBCH development stages 71 to 97.

In one embodiment, the use of Venturia inequalis inoculum reduction compositions containing any combination as disclosed in Listing 1 is disclosed on a rosette of leaves at BBCH developmental stages 71 to 97.

In one embodiment, the use of Venturia inequalis inoculum reducing compositions containing any combination as disclosed in Listing 1 is disclosed on the leaves of shoots at fruit stages BBCH 71 to 97.

In one embodiment, the use of Venturia inequalis inoculum reducing compositions containing any combination as disclosed in List 1 is disclosed on the leaves of shoots at fruit stages BBCH 71 to 97.

In one embodiment, the use of Venturia inequalis inoculum reducing compositions containing fluopyram and fosetyl aluminum on leaves at BBCH development stages 71 to 97 is disclosed.

In one embodiment, the use of Venturia inequalis inoculum reducing compositions containing fluopyram and fosetyl aluminum on a rosette of leaves at BBCH developmental stages 71 to 97 is disclosed.

In one embodiment, the use of Venturia inequalis inoculum reducing compositions containing fluopyram and fosetyl aluminum is disclosed on the leaves of shoots at fruit stages BBCH 71 to 97.

In one embodiment, the use of Venturia inequalis inoculum reducing compositions containing fluopyram and fosetyl aluminum is disclosed on the leaves of shoots at BBCH fruit stages 71 to 97.

Compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, may be present in their commercially available formulations and in forms of application prepared from these compositions, in the form of a mixture with other active ingredients such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, protectants, fertilizers, biological control agents, resistance enhancers or semi-chemicals.

Compositions containing fluopyram and fosetyl aluminum may be present in their commercially available formulations and in dosage forms prepared from these formulations, as a mixture with other active ingredients such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, protective agents, fertilizers, biological control agents, resistance enhancers or semi-chemicals.

In addition, the reported beneficial effect of compositions containing fluopyram and fosetyl aluminum in controlling mosaic rot in apple trees may be facilitated by additional treatment with insecticidal, fungicidal or bactericidal active ingredients, resistance enhancers and biological control agents.

Combinations of compositions containing fluopyram and fosetyl aluminum with substances such as insecticides, fungicides, resistance enhancers and bactericides, fertilizers, growth regulators and biological control agents may also find use in the control of mosaic rot in apple trees.

In addition, compositions containing fluopyram and fosetyl aluminum may contain one or more additional fungicides, which may be selected from the group consisting of:

(1) Ergosterol biosynthesis inhibitors, for example (1.1) aldimorph (1704-28-5), (1.2) asaconazole (60207-31-0), (1.3) bitertanol (55179-31-2), (1.4) bromuconazole (116255 -48-2), (1.5) cyproconazole (113096-99-4), (1.6) diclobutrazol (75736-33-3), (1.7) difenoconazole (119446-68-3), (1.8) diniconazole (83657-24 -3), (1.9) diniconazole-M (83657-18-5), (1.10) dodemorph (1593-77-7), (1.11) dodemorph acetate (31717-87-0), (1.12) epoxiconazole (106325- 08-0), (1.13) etaconazole (60207-93-4), (1.14) fenarimol (60168-88-9), (1.15) fenbuconazole (114369-43-6), (1.16) fenhexamide (126833-17- 8), (1.17) fenpropidine (67306-00-7), (1.18) fenpropimorph (67306-03-0), (1.19) fluquinconazole (136426-54-5), (1.20) flurprimidol (56425-91-3) , (1.21) flusilazole (85509-19-9), (1.22) flutriafol (76674-21-0), (1.23) furconazole (112839-33-5), (1.24) furconazole-cis (112839-32-4) , (1.25) hexaconazole (79983-71-4), (1.26) imazalil (60534-80-7), (1.27) imazalil sulfate (58594-72-2), (1.28) imibenconazole (86598-92-7), (1.29) ipconazole (125225-28-7), (1.30) metconazole (125116-23-6), (1.31) myclobutanil (88671-89-0), (1.32) naftifine (65472-88-0), (1.33 ) nuarimol (63284-71-9), (1.34) oxpoconazole (174212-12-5), (1.35) paclobutrazol (76738-62-0), (1.36) pefurazoate (101903-30-4), (1.37) penconazole (66246-88-6), (1.38) piperaline (3478-94-2), (1.39) prochloraz (67747-09-5), (1.40) propiconazole (60207-90-1), (1.41) prothioconazole (178928 -70-6), (1.42) pyributicarb (88678-67-5), (1.43) pyrifenox (88283-41-4), (1.44) quinconazole (103970-75-8), (1.45) simeconazole (149508-90 -7), (1.46) spiroxamine (118134-30-8), (1.47) tebuconazole (107534-96-3), (1.48) terbinafine (91161-71-6), (1.49) tetraconazole (112281-77-3 ), (1.50) triadimefon (43121-43-3), (1.51) triadimenol (89482-17-7), (1.52) tridemorph (81412-43-3), (1.53) triflumizole (68694-11-1), (1.54) triforin (26644-46-2), (1.55) triticonazole (131983-72-7), (1.56) uniconazole (83657-22-1), (1.57) uniconazole-p (83657-17-4), (1.58) viniconazole (77174-66-4), (1.59) voriconazole (137234-62-9), (1.60) 1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1- yl)cycloheptanol (129586-32-9), (1.61) methyl 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazol-5-carboxylate (110323-95 -0), (1.62) N'-{5-(difluoromethyl)-2-methyl-4-[3-(trimethylsilyl)propoxy]phenyl}-N-ethyl-N-methylimidoformamide, (1.63) N-ethyl-N -methyl-N'-{2-methyl-5-(trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}imidoformamide and (1.64) O-[1-(4-methoxyphenoxy)-3,3-dimethylbutane -2-yl] 1H-imidazol-1-carbothioate (111226-71-2).

(2) inhibitors of complex I or II of the respiratory chain, for example (2.1) bixafen (581809-46-3), (2.2) boscalid (188425-85-6), (2.3) carboxin (5234-68-4), (2.4 ) diflumetorim (130339-07-0), (2.5) fenfuram (24691-80-3), (2.6) fluopyram (658066-35-4), (2.7) flutolanil (66332-96-5), (2.8) fluxapyroxad (907204-31-3), (2.9) furamethpyr (123572-88-3), (2.10) furmecyclox (60568-05-0), (2.11) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti- epimeric racemate 1RS,4SR,9SR) (881685-58-1), (2.12) isopyrase (anti-epimeric racemate 1RS,4SR,9SR), (2.13) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.14 ) isopyrase (anti-epimeric enantiomer 1S,4R,9R), (2.15) isopyrase (syn-epimeric racemate 1RS,4SR,9RS), (2.16) isopyrase (syn-epimeric enantiomer 1R,4S,9R), (2.17) isopyrase (syn-epimeric enantiomer 1S,4R,9S), (2.18) mepronil (55814-41-0), (2.19) oxycarboxin (5259-88-1), (2.20) penflufen (494793-67-8), (2.21 ) penthiopyrad (183675-82-3), (2.22) sedaxane (874967-67-6), (2.23) tifluzamide (130000-40-7), (2.24) 1-methyl-N-[2-(1,1 ,2,2-tetrafluoroethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (2.25) 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2 -tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide, (2.26) 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]- 1-methyl-1H-pyrazol-4-carboxamide, (2.27) N-[1-(2,4-dichlorophenyl)-1-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole -4-carboxamide (1092400-95-7) (WO 2008148570), (2.28) 5,8-difluoro-N-[2-(2-fluoro-4-{[4-(trifluoromethyl)pyridin-2-yl] oxy}phenyl)ethyl]quinazolin-4-amine (1210070-84-0) (WO2010025451), (2.29) N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methannaphthalene- 5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.30) N-[(1S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro -1,4-methannaphthalene-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and (2.31) N-[(1R,4S)-9-(dichloromethylene)-1, 2,3,4-tetrahydro-1,4-methannaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide.

(3) complex III respiratory chain inhibitors, for example (3.1) ametokradine (865318-97-4), (3.2) amisulbrom (348635-87-0), (3.3) azoxystrobin (131860-33-8), (3.4) cyazofamide (120116-88-3), (3.5) coumethoxystrobin (850881-30-0), (3.6) cumoxystrobin (850881-70-8), (3.7) dimoxystrobin (141600-52-4), (3.8) enestroburin (238410 -11-2) (WO 2004/058723), (3.9) famoxadone (131807-57-3) (WO 2004/058723), (3.10) fenamidone (161326-34-7) (WO 2004/058723), (3.11 ) phenoxystrobin (918162-02-4), (3.12) fluoxastrobin (361377-29-9) (WO 2004/058723), (3.13) kresoxim-methyl (143390-89-0) (WO 2004/058723), (3.14 ) metominostrobin (133408-50-1) (WO 2004/058723), (3.15) orysastrobin (189892-69-1) (WO 2004/058723), (3.16) ricoxystrobin (117428-22-5) (WO 2004/058723 ), (3.17) pyraclostrobin (175013-18-0) (WO 2004/058723), (3.18) pyramethostrobin (915410-70-7) (WO 2004/058723), (3.19) pyraoxystrobin (862588-11-2) ( WO 2004/058723), (3.20) pyribencarb (799247-52-2) (WO 2004/058723), (3.21) triclopyricarb (902760-40-1), (3.22) trifloxystrobin (141517-21-7) (WO 2004 /058723), (3.23) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)-2-(methoxyimino)-N -methylethanamide (WO 2004/058723), (3.24) (2E)-2-(methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene }amino)oxy]methyl}phenyl)ethanamide (WO 2004/058723), (3.25) (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3 -(trifluoromethyl)phenyl]ethoxy}imino)methyl]phenyl}ethanamide (158169-73-4), (3.26) (2E)-2-{2-[({[(1E)-1-(3-{[ (E)-1-fluoro-2-phenylethenyl]oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylethanamide (326896-28-0), (3.27) (2E) -2-{2-[({[(2E,3E)-4-(2,6-dichlorophenyl)but-3-en-2-ylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)- N-methylethanamide, (3.28) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)pyridin-3-carboxamide (119899-14-8), ( 3.29) 5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]methyl}phenyl)-2,4-dihydro- 3H-1,2,4-triazol-3-one, (3.30) methyl (2E)-2-{2-[({cyclopropyl[(4-methoxyphenyl)imino]methyl}sulfanyl)methyl]phenyl}-3- methoxyprop-2-enoate (149601-03-6), (3.31) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-(formylamino)-2-hydroxybenzamide (226551-21-9), ( 3.32) 2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (173662-97-0) and (3.33) (2R)-2-{2-[(2 ,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (394657-24-0).

(4) Mitosis and cell division inhibitors, e.g. (4.1) benomyl (17804-35-2), (4.2) carbendazim (10605-21-7), (4.3) chlorphenazole (3574-96-7), (4.4) diethofencarb (87130-20-9), (4.5) ethaboxam (162650-77-3), (4.6) fluopicolide (239110-15-7), (4.7) fuberidazole (3878-19-1), (4.8) pencicuron (66063 -05-6), (4.9) thiabendazole (148-79-8), (4.10) thiophanate-methyl (23564-05-8), (4.11) thiophanate (23564-06-9), (4.12) zoxamide (156052 -68-5), (4.13) 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a ]pyrimidine (214706-53-3) and (4.14) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine (1002756-87- 7).

(5) Compounds capable of multisite action, such as (5.1) Bordeaux mixture (8011-63-0), (5.2) captafol (2425-06-1), (5.3) captan (133-06-2) (WO 02/12172), (5.4) chlorothalonil (1897-45-6), (5.5) copper hydroxide (20427-59-2), (5.6) copper naphthenate (1338-02-9), (5.7) copper oxide (1317 -39-1), (5.8) copper oxychloride (1332-40-7), (5.9) copper(2+) sulfate (7758-98-7), (5.10) dichlorofluanid (1085-98-9), (5.11 ) dithianone (3347-22-6), (5.12) dodine (2439-10-3), (5.13) free base dodine, (5.14) ferbam (14484-64-1), (5.15) fluorofolpet (719- 96-0), (5.16) folpet (133-07-3), (5.17) guazatine (108173-90-6), (5.18) guazatine acetate, (5.19) iminoctadine (13516-27-3), (5.20) iminoctadine albesilate (169202-06-6), (5.21) iminoctadine triacetate (57520-17-9), (5.22) mancopper (53988-93-5), (5.23) mancozeb (8018-01-7), (5.24) maneb (12427-38-2), (5.25) methiram (9006-42-2), (5.26) methiram zinc (9006-42-2), (5.27) oxine-copper (10380-28-6), (5.28 ) propamidine (104-32-5), (5.29) propineb (12071-83-9), (5.30) sulfur and sulfur preparations, including calcium polysulfide (7704-34-9), (5.31) thiram (137-26- 8), (5.32) tolylfluanid (731-27-1), (5.33) zineb (12122-67-7) and (5.34) ziram (137-30-4).

(6) Compounds capable of inducing immunological protection, e.g. (6.1) acibenzolar-S-methyl (135158-54-2), (6.2) isothianyl (224049-04-1), (6.3) probenazole (27605-76-1 ) and (6.4) tiadinyl (223580-51-6).

(7) Inhibitors of amino acid and/or protein biosynthesis, for example, (7.1) endoprim (23951-85-1), (7.2) blasticidin-S (2079-00-7), (7.3) cyprodinil (121552-61-2) , (7.4) kasugamycin (6980-18-3), (7.5) kasugamycin hydrochloride hydrate (19408-46-9), (7.6) mepanipyrim (110235-47-7), (7.7) pyrimethanil (53112-28-0) and (7.8) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline (861647-32-7) (WO2005070917).

(8) ATP production inhibitors, for example, (8.1) fentine acetate (900-95-8), (8.2) fentine chloride (639-58-7), (8.3) fentine hydroxide (76-87-9) and (8.4 ) silthiopham (175217-20-6).

(9) Cell wall synthesis inhibitors, e.g. (9.1) benthiavalicarb (177406-68-7), (9.2) dimethomorph (110488-70-5), (9.3) flumorph (211867-47-9), (9.4) iprovalicarb (140923-17-7), (9.5) mandipropamide (374726-62-2), (9.6) polyoxins (11113-80-7), (9.7) polyoxorim (22976-86-9), (9.8) validamycin A ( 37248-47-8) and (9.9) valifenalate (283159-94-4; 283159-90-0).

(10) Inhibitors of lipid and membrane synthesis, for example (10.1) biphenyl (92-52-4), (10.2) chlorneb (2675-77-6), (10.3) dicloran (99-30-9), (10.4) edifenphos (17109-49-8), (10.5) etridiazole (2593-15-9), (10.6) iodocarb (55406-53-6), (10.7) iprobenphos (26087-47-8), (10.8) isoprothiolane (50512 -35-1), (10.9) propamocarb (25606-41-1), (10.10) propamocarb hydrochloride (25606-41-1), (10.11) prothiocarb (19622-08-3), (10.12) pyrazophos (13457- 18-6), (10.13) quintozene (82-68-8), (10.14) tecnazene (117-18-0) and (10.15) tolclofos-methyl (57018-04-9).

(11) Melanin biosynthesis inhibitors, for example, (11.1) carpropamide (104030-54-8), (11.2) diclocymet (139920-32-4), (11.3) phenoxanyl (115852-48-7), (11.4) phthalide ( 27355-22-2), (11.5) pyroquilone (57369-32-1), (11.6) tricyclazole (41814-78-2) and (11.7) 2,2,2-trifluoroethyl {3-methyl-1-[( 4-methylbenzoyl)amino]butan-2-yl}carbamate (851524-22-6) (WO2005042474).

(12) Nucleic acid synthesis inhibitors, for example (12.1) benalaxyl (71626-11-4), (12.2) benalaxyl-M (kyralaxyl) (98243-83-5), (12.3) bupirimate (41483-43-6), (12.4) closilacone (67932-85-8), (12.5) dimethyromol (5221-53-4), (12.6) ethirimol (23947-60-6), (12.7) furalaxyl (57646-30-7), (12.8 ) hymexazole (10004-44-1), (12.9) metalaxyl (57837-19-1), (12.10) metalaxyl-M (mefenoxam) (70630-17-0), (12.11) ofurac (58810-48-3) , (12.12) oxadixyl (77732-09-3) and (12.13) oxolinic acid (14698-29-4).

(13) Signal transduction inhibitors, e.g. (13.1) chlozolinate (84332-86-5), (13.2) fenpiclonil (74738-17-3), (13.3) fludioxonil (131341-86-1), (13.4) iprodione ( 36734-19-7), (13.5) procymodone (32809-16-8), (13.6) quinoxifene (124495-18-7) and (13.7) vinclozolin (50471-44-8).

(14) Compounds capable of acting as an uncoupling agent, e.g. (14.1) binapacryl (485-31-4), (14.2) dinocap (131-72-6), (14.3) ferimzone (89269-64-7), (14.4) fluazinam (79622-59-6) and (14.5) meptyldinocap (131-72-6).

(15) Additional compounds, for example, (15.1) benthiazole (21564-17-0), (15.2) betoxazine (163269-30-5), (15.3) capsimycin (70694-08-5), (15.4) carvone (99 -49-0), (15.5) quinomethionate (2439-01-2), (15.6) pyriophenone (chlazaphenone) (688046-61-9), (15.7) kufraneb (11096-18-7), (15.8) cyflufenamide ( 180409-60-3), (15.9) cymoxanil (57966-95-7), (15.10) cyprosulfamide (221667-31-8), (15.11) dazomet (533-74-4), (15.12) debacarb (62732- 91-6), (15.13) dichlorphene (97-23-4), (15.14) diclomesine (62865-36-5), (15.15) diphenzoquat (49866-87-7), (15.16) diphenzoquat methyl sulfate (43222-48 -6), (15.17) diphenylamine (122-39-4), (15.18) ecomat, (15.19) phenpyrazamine (473798-59-3), (15.20) flumetover (154025-04-4), (15.21) fluorimide ( 41205-21-4), (15.22) flusulfamide (106917-52-6), (15.23) flutianyl (304900-25-2), (15.24) fosetyl-aluminum (39148-24-8), (15.25) fosetyl- calcium, (15.26) fosetyl sodium (39148-16-8), (15.27) hexachlorobenzene (118-74-1), (15.28) irumamycin (81604-73-1), (15.29) metasulfocarb (66952-49-6 ), (15.30) methyl isothiocyanate (556-61-6), (15.31) metrafenone (220899-03-6), (15.32) mildiomycin (67527-71-3), (15.33) natamycin (7681-93-8), (15.34) nickel dimethyldithiocarbamate (15521-65-0), (15.35) nitrotal isopropyl (10552-74-6), (15.36) octylinone (26530-20-1), (15.37) oxamocarb (917242-12-7) , (15.38) oxyphenthiine (34407-87-9), (15.39) pentachlorophenol and salts (87-86-5), (15.40) phenothrin, (15.41) phosphoric acid and its salts (13598-36-2), (15.42 ) propamocarb-fosetylate, (15.43) propanosyn-sodium (88498-02-6), (15.44) proquinazide (189278-12-4), (15.45) pyrimorph (868390-90-3), (15.45e) (2E) -3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one (1231776-28-5), ( 15.45z) (2Z)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one (1231776- 29-6), (15.46) pyrrolnitrine (1018-71-9) (EP-A 1 559 320), (15.47) tebufloquine (376645-78-2), (15.48) teclophthalam (76280-91-6), ( 15.49) tolnifanide (304911-98-6), (15.50) triazoxide (72459-58-6), (15.51) trichlamide (70193-21-4), (15.52) sarylamide (84527-51-5), (15.53) (3S,6S,7R,8R)-8-benzyl-3-[({3-[(isobutyryloxy)methoxy]-4-methoxypyridin-2-yl}carbonyl)amino]-6-methyl-4,9-dioxo -1,5-dioxonan-7-yl 2-methylpropanoate (517875-34-2) (WO2003035617), (15.54) 1-(4-{4-[(5R)-5-(2,6-difluorophenyl)- 4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazole -1-yl]ethanone (1003319-79-6) (WO 2008013622), (15.55) 1-(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro- 1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (1003319-80-9) (WO 2008013622), (15.56) 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl] -1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (1003318-67-9) (WO 2008013622 ), (15.57) 1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl 1H-imidazol-1-carboxylate (111227-17-9), (15.58) 2,3,5,6-tetrachloro- 4-(methylsulfonyl)pyridine (13108-52-6), (15.59) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one (221451-58-7), ( 15.60) 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetron, ( 15.61) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5R)-5-phenyl-4,5-dihydro-1,2 -oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone (1003316-53-7) (WO 2008013622), (15.62) 2-[5-methyl-3-( trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3- thiazol-2-yl}piperidin-1-yl)ethanone (1003316-54-8) (WO 2008013622), (15.63) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]- 1-{4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidin-1-yl}ethanone (1003316- 51-5) (WO 2008013622), (15.64) 2-butoxy-6-iodo-3-propyl-4H-chromen-4-one, (15.65) 2-chloro-5-[2-chloro-1-(2 ,6-difluoro-4-methoxyphenyl)-4-methyl-1H-imidazol-5-yl]pyridine, (15.66) 2-phenylphenol and salts (90-43-7), (15.67) 3-(4,4, 5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline (861647-85-0) (WO2005070917), (15.68) 3,4,5-trichloropyridin-2,6-dicarbonitrile (17824 -85-0), (15.69) 3-[5-(4-chlorophenyl)-2,3-dimethyl-1,2-oxazolidin-3-yl]pyridine, (15.70) 3-chloro-5-(4- chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, (15.71) 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine, (15.72) 5-amino -1,3,4-thiadiazol-2-thiol, (15.73) 5-chloro-N'-phenyl-N'-(prop-2-yn-1-yl)thiophene-2-sulfonohydrazide (134-31-6 ), (15.74) 5-fluoro-2-[(4-fluorobenzyl)oxy]pyrimidin-4-amine (1174376-11-4) (WO2009094442), (15.75) 5-fluoro-2-[(4-methylbenzyl) oxy]pyrimidin-4-amine (1174376-25-0) (WO2009094442), (15.76) 5-methyl-6-octyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, ( 15.77) ethyl (2Z)-3-amino-2-cyano-3-phenylprop-2-enoate, (15.78) N'-(4-{[3-(4-chlorobenzyl)-1,2,4-thiadiazol- 5-yl]oxy}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (15.79) N-(4-chlorobenzyl)-3-[3-methoxy-4-(prop-2-yne-1 -yloxy)phenyl]propanamide, (15.80) N-[(4-chlorophenyl)(cyano)methyl]-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, (15.81 ) N-[(5-bromo-3-chloropyridin-2-yl)methyl]-2,4-dichloropyridin-3-carboxamide, (15.82) N-[1-(5-bromo-3-chloropyridin-2-yl )ethyl]-2,4-dichloropyridin-3-carboxamide, (15.83) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2-fluoro-4-iodopyridin-3-carboxamide, (15.84) N-{(E)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide (221201-92-9), (15.85) N-{( Z)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide (221201-92-9), (15.86) N'-{4-[(3-tert -butyl-4-cyano-1,2-thiazol-5-yl)oxy]-2-chloro-5-methylphenyl}-N-ethyl-N-methylimidoformamide, (15.87) N-methyl-2-(1-{ [5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3,4-tetrahydronaphthalene-1-yl)-1,3- thiazol-4-carboxamide (922514-49-6) (WO 2007014290), (15.88) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl }piperidin-4-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazol-4-carboxamide (922514-07-6) (WO 2007014290) , (15.89) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1S)-1 ,2,3,4-tetrahydronaphthalene-1-yl]-1,3-thiazol-4-carboxamide (922514-48-5) (WO 2007014290), (15.90) pentyl {6-[({[(1-methyl -1H-tetrazol-5-yl)(phenyl)methylidene]amino}oxy)methyl]pyridin-2-yl}carbamate, (15.91) phenazine-1-carboxylic acid, (15.92) quinolin-8-ol (134-31 -6), (15.93) quinolin-8-ol sulfate (2:1) (134-31-6) and (15.94) tert-butyl {6-[({[(1-methyl-1H-tetrazol-5- yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate.

(16) Additional compounds, for example, (16.1) 1-methyl-3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazol-4-carboxamide, (16.2) N- (4'-chlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (16.3) N-(2',4'-dichlorobiphenyl-2-yl)-3- (difluoromethyl)-1-methyl-1H-pyrazol-4-carboxamide, (16.4) 3-(difluoromethyl)-1-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazol-4 -carboxamide, (16.5) N-(2',5'-difluorobiphenyl-2-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (16.6) 3-(difluoromethyl)-1 -methyl-N-[4'-(prop-1-yn-1-yl)biphenyl-2-yl]-1H-pyrazol-4-carboxamide (known from WO 2004/058723), (16.7) 5-fluoro- 1,3-Dimethyl-N-[4'-(prop-1-yn-1-yl)biphenyl-2-yl]-1H-pyrazol-4-carboxamide (known from WO 2004/058723), (16.8) 2 -chloro-N-[4'-(prop-1-yn-1-yl)biphenyl-2-yl]pyridin-3-carboxamide (known from WO 2004/058723), (16.9) 3-(difluoromethyl)-N -[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.10) N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004 /058723), (16.11) 3-(difluoromethyl)-N-(4'-ethynylbiphenyl-2-yl)-1-methyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.12) N -(4'-ethynylbiphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.13) 2-chloro-N-(4' -ethynylbiphenyl-2-yl)pyridin-3-carboxamide (known from WO 2004/058723), (16.14) 2-chloro-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl -2-yl]pyridin-3-carboxamide (known from WO 2004/058723), (16.15) 4-(difluoromethyl)-2-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]-1, 3-thiazol-5-carboxamide (known from WO 2004/058723), (16.16) 5-fluoro-N-[4'-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2- yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.17) 2-chloro-N-[4'-(3-hydroxy-3-methylbut-1-yne -1-yl)biphenyl-2-yl]pyridin-3-carboxamide (known from WO 2004/058723), (16.18) 3-(difluoromethyl)-N-[4'-(3-methoxy-3-methylbut-1 -in-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.19) 5-fluoro-N-[4'-(3- methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide (known from WO 2004/058723), (16.20) 2-chloro- N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]pyridin-3-carboxamide (known from WO 2004/058723), (16.21) (5-bromo -2-methoxy-4-methylpyridin-3-yl)(2,3,4-trimethoxy-6-methylphenyl)ethanone (known from EP-A 1 559 320), (16.22) N-[2-(4-{ [3-(4-chlorophenyl)prop-2-yn-1-yl]oxy}-3-methoxyphenyl)ethyl]-N2-(methylsulfonyl)valinamide (220706-93-4), (16.23) 4-oxo-4 -[(2-phenylethyl)amino]butanoic acid and (16.24) but-3-yn-1-yl {6-[({[(Z)-(1-methyl-1H-tetrazol-5-yl)(phenyl )methylene]amino}oxy)methyl]pyridin-2-yl}carbamate.

All named combination partners of classes (1) - (16), as well as fluopyram and fosetyl aluminum according to the present invention can, if their functional groups provide this, optionally form salts with suitable bases and acids.

In one embodiment, a composition containing fluopyram and fosetyl aluminum may contain one or more additional fungicides, which may be selected from the group consisting of:

(1) Ergosterol biosynthesis inhibitors, e.g. aldimorph, azaconazole, bitertanol, bromuconazole, cyproconazole, diclobutrazol, difenoconazole, diniconazole, diniconazole-M, dodemorph, dodemorph-acetate, epoxiconazole, etaconazole, fenarimol, fenbuconazole, fenhexamide, fenpropidine, fen propimorph, fluquinconazole , flurprimidol, flusilazole, flutriafol, furconazole, furconazole-cis, hexaconazole, imazalil, imazalil-sulfate, imibenconazole, ipconazole, metconazole, myclobutanil, naftifine, nuarimol, oxpoconazole, paclobutrazol, pefurazoate, penconazole, piperaline, prokhlo times, propiconazole, prothioconazole, piributicarb , pirifenox, quinconazole, simeconazole, spiroxamine, tebuconazole, terbinafine, tetraconazole, triadimefon, triadimenol, tridemorph, triflumizole, triforin, triticonazole, uniconazole, uniconazole-p, viniconazole, voriconazole, 1-(4-chlorophenyl)-2-(1H- 1,2,4-triazol-1-yl)cycloheptanol, methyl 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazol-5-carboxylate, N'- {5-(difluoromethyl)-2-methyl-4-[3-(trimethylsilyl)propoxy]phenyl}-N-ethyl-N-methylimidoformamide, N-ethyl-N-methyl-N'-{2-methyl-5- (trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}imidoformamide and O-[1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl]1H-imidazol-1-carbothioate and

(2) inhibitors of complex I or II of the respiratory chain, for example (2.1) bixafen (581809-46-3), (2.2) boscalid (188425-85-6), (2.3) carboxin (5234-68-4), (2.4 ) diflumetorim (130339-07-0), (2.5) fenfuram (24691-80-3), (2.6) fluopyram (658066-35-4), (2.7) flutolanil (66332-96-5), (2.8) fluxapyroxad (907204-31-3), (2.9) furamethpyr (123572-88-3), (2.10) furmecyclox (60568-05-0), (2.11) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti- epimeric racemate 1RS,4SR,9SR) (881685-58-1), (2.12) isopyrase (anti-epimeric racemate 1RS,4SR,9SR), (2.13) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (2.14 ) isopyrase (anti-epimeric enantiomer 1S,4R,9R), (2.15) isopyrase (syn-epimeric racemate 1RS,4SR,9RS), (2.16) isopyrase (syn-epimeric enantiomer 1R,4S,9R), (2.17) isopyrase (syn-epimeric enantiomer 1S,4R,9S), (2.18) mepronil (55814-41-0), (2.19) oxycarboxin (5259-88-1), (2.20) penflufen (494793-67-8), (2.21 ) penthiopyrad (183675-82-3), (2.22) sedaxane (874967-67-6), (2.23) tifluzamide (130000-40-7), (2.24) 1-methyl-N-[2-(1,1 ,2,2-tetrafluoroethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (2.25) 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2 -tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide, (2.26) 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]- 1-methyl-1H-pyrazol-4-carboxamide, (2.27) N-[1-(2,4-dichlorophenyl)-1-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole -4-carboxamide (1092400-95-7) (WO 2008148570), (2.28) 5,8-difluoro-N-[2-(2-fluoro-4-{[4-(trifluoromethyl)pyridin-2-yl] oxy}phenyl)ethyl]quinazolin-4-amine (1210070-84-0) (WO2010025451), (2.29) N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methannaphthalene- 5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (2.30) N-[(1S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro -1,4-methannaphthalene-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and (2.31) N-[(1R,4S)-9-(dichloromethylene)-1, 2,3,4-tetrahydro-1,4-methannaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide.

(3) complex III respiratory chain inhibitors, for example (3.1) ametokradine (865318-97-4), (3.2) amisulbrom (348635-87-0), (3.3) azoxystrobin (131860-33-8), (3.4) cyazofamide (120116-88-3), (3.5) coumethoxystrobin (850881-30-0), (3.6) cumoxystrobin (850881-70-8), (3.7) dimoxystrobin (141600-52-4), (3.8) enestroburin (238410 -11-2) (WO 2004/058723), (3.9) famoxadone (131807-57-3) (WO 2004/058723), (3.10) fenamidone (161326-34-7) (WO 2004/058723), (3.11 ) phenoxystrobin (918162-02-4), (3.12) fluoxastrobin (361377-29-9) (WO 2004/058723), (3.13) kresoxim-methyl (143390-89-0) (WO 2004/058723), (3.14 ) metominostrobin (133408-50-1) (WO 2004/058723), (3.15) orysastrobin (189892-69-1) (WO 2004/058723), (3.16) ricoxystrobin (117428-22-5) (WO 2004/058723 ), (3.17) pyraclostrobin (175013-18-0) (WO 2004/058723), (3.18) pyramethostrobin (915410-70-7) (WO 2004/058723), (3.19) pyraoxystrobin (862588-11-2) ( WO 2004/058723), (3.20) pyribencarb (799247-52-2) (WO 2004/058723), (3.21) triclopyricarb (902760-40-1), (3.22) trifloxystrobin (141517-21-7) (WO 2004 /058723), (3.23) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)-2-(methoxyimino)-N -methylethanamide (WO 2004/058723), (3.24) (2E)-2-(methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene }amino)oxy]methyl}phenyl)ethanamide (WO 2004/058723), (3.25) (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3 -(trifluoromethyl)phenyl]ethoxy}imino)methyl]phenyl}ethanamide (158169-73-4), (3.26) (2E)-2-{2-[({[(1E)-1-(3-{[ (E)-1-fluoro-2-phenylethenyl]oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylethanamide (326896-28-0), (3.27) (2E) -2-{2-[({[(2E,3E)-4-(2,6-dichlorophenyl)but-3-en-2-ylidene]amino}oxy)methyl]phenyl}-2-(methoxyimino)- N-methylethanamide, (3.28) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)pyridin-3-carboxamide (119899-14-8), ( 3.29) 5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]methyl}phenyl)-2,4-dihydro- 3H-1,2,4-triazol-3-one, (3.30) methyl (2E)-2-{2-[({cyclopropyl[(4-methoxyphenyl)imino]methyl}sulfanyl)methyl]phenyl}-3- methoxyprop-2-enoate (149601-03-6), (3.31) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-(formylamino)-2-hydroxybenzamide (226551-21-9), ( 3.32) 2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (173662-97-0) and (3.33) (2R)-2-{2-[(2 ,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide (394657-24-0) and

(15) additional compounds, e.g. benthiazole, betoxazine, capsimycin, carvone quinomethionate, iriophenone (chlazaphenone), kufraneb, cyflufenamide, cymoxanil, cyprosulfamide, dazomet, debacarb, dichlorfen, diclomezine, difenzoquat, difenzoquat methylsulfate, diphenylamine, ecomate, fenpyrase min, flumetover, fluorimide, flusulfamide, flutianil, fosetyl aluminum, fosetyl calcium, fosetyl sodium, hexachlorobenzene, irumamycin, metasulfocarb, methyl isothiocyanate, metrafenone, mildiomycin, natamycin, nickel dimethyldithiocarbamate, nitrotal isopropyl, octylinone, oxamocarb, oxyphenthiine, pen tachlorophenol and salts, phenothrin , phosphoric acid and its salts, propamocarb-fosetylate, propanosyn-sodium, proquinazide, pyrimorph, (2E)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholine- 4-yl)prop-2-en-1-one, (2Z)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop -2-en-1-one, pyrrolnitrin, tebufloquine, teklophthalam, tolnifanide, triazoxide, trichlamide, sarylamide, (3S,6S,7R,8R)-8-benzyl-3-[({3-[(isobutyryloxy)methoxy] -4-methoxypyridin-2-yl}carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl 2-methylpropanoate, 1-(4-{4-[(5R)- 5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl -3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, 1-(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2- Oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, 1-( 4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)- 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, 1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl 1H-imidazol-1-carboxylate, 2, 3,5,6-tetrachloro-4-(methylsulfonyl)pyridine, 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one, 2,6-dimethyl-1H,5H- [1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetron, (2-[5-methyl-3-(trifluoromethyl) -1H-pyrazol-1-yl]-1-(4-{4-[(5R)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol- 2-yl}piperidin-1-yl)ethanone, 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl -4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, 2-[5-methyl-3-(trifluoromethyl)-1H -pyrazol-1-yl]-1-{4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidin- 1-yl}ethanone, 2-butoxy-6-iodo-3-propyl-4H-chromen-4-one, 2-chloro-5-[2-chloro-1-(2,6-difluoro-4-methoxyphenyl) -4-methyl-1H-imidazol-5-yl]pyridine, 2-phenylphenol and salts, 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, 3,4,5-trichloropyridin-2,6-dicarbonitrile, 3-[5-(4-chlorophenyl)-2,3-dimethyl-1,2-oxazolidin-3-yl]pyridine, 3-chloro-5-( 4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine, 5-amino-1,3 ,4-thiadiazol-2-thiol, 5-chloro-N'-phenyl-N'-(prop-2-yn-1-yl)thiophene-2-sulfonohydrazide, 5-fluoro-2-[(4-fluorobenzyl) oxy]pyrimidin-4-amine, 5-fluoro-2-[(4-methylbenzyl)oxy]pyrimidin-4-amine, 5-methyl-6-octyl[1,2,4]triazolo[1,5-a] pyrimidin-7-amine, ethyl (2Z)-3-amino-2-cyano-3-phenylprop-2-enoate, N'-(4-{[3-(4-chlorobenzyl)-1,2,4-thiadiazole -5-yl]oxy}-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, N-(4-chlorobenzyl)-3-[3-methoxy-4-(prop-2-yn-1-yloxy )phenyl]propanamide, N-[(4-chlorophenyl)(cyano)methyl]-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, N-[(5-bromo -3-chloropyridin-2-yl)methyl]-2,4-dichloropyridin-3-carboxamide, N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2,4-dichloropyridin-3 -carboxamide, N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2-fluoro-4-iodopyridin-3-carboxamide, N-{(E)-[(cyclopropylmethoxy)imino][ 6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phenylacetamide, N-{(Z)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2- phenylacetamide, N'-{4-[(3-tert-butyl-4-cyano-1,2-thiazol-5-yl)oxy]-2-chloro-5-methylphenyl}-N-ethyl-N-methylimidoformamide, (N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3,4- tetrahydronaphthalene-1-yl)-1,3-thiazol-4-carboxamide, (N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidine -4-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazol-4-carboxamide, N-methyl-2-(1-{[5 -methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1S)-1,2,3,4-tetrahydronaphthalene-1-yl]-1, 3-thiazol-4-carboxamide, pentyl {6-[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylidene]amino}oxy)methyl]pyridin-2-yl}carbamate, phenazin- 1-carboxylic acid, (quinolin-8-ol, quinolin-8-ol sulfate (2:1) and tert-butyl {6-[({[(1-methyl-1H-tetrazol-5-yl)(phenyl) methylene]amino}oxy)methyl]pyridin-2-yl}carbamate.

In one embodiment, the composition containing fluopyram and fosetyl aluminum may contain one or more additional fungicides, which may be selected from the group consisting of benzovindiflupyr, bixafen, fluxapyroxad, dithianone, fludioxonil, tebuconazole, prothioconazole, difenconazole, epoxiconazole, ipconazole, propamocarb-fosetylate, trifloxystrobin, mycobutanil, captan, mancozeb, propineb, boscalid, pentiopyrad, cyprodinil, kresoxim-methyl, mefentrifluconazole, ipfentrifluconazole, inpirfluxam, isoflucipram, fluindapir, quinofumelin, trifloxystrobin, f osetil aluminum, pyrimethanil, Bacillus subtilis strain QST713 (sold under trade name Serenade, Bayer CropScience).

Compositions

Compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, may additionally contain at least one other additional component, such as excipients, solvents, media or carriers, fillers, surfactants or additives, all of which are agriculturally applicable.

According to the invention, the term "carrier" or "medium" should be understood as meaning a natural or synthetic, organic or inorganic substance that is mixed or combined with the active compounds for better applicability, in particular for application to plants or plant parts or seeds. The carrier or medium, which may be solid or liquid, is usually inert and must be suitable for agricultural use. Suitable solid or liquid media/carriers include, for example, ammonium salts and natural particulate minerals such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and particulate synthetic minerals such as micronized silica, alumina and natural or synthetic silicates, resins, waxes, solid fertilizers, water, alcohols, especially butanol, organic solvents, mineral oils and vegetable oils, as well as their derivatives. Mixtures of such carriers or media may also be used. Solid carriers/media suitable for granules are: for example, crushed and fractionated natural minerals such as calcite, marble, pumice, sepiolite, dolomite, as well as synthetic granules of inorganic and organic flour, as well as granules of organic material such as sawdust, coconut shells, corn cobs and tobacco stalks. Suitable liquefied gaseous vehicles or media are liquids that are gaseous at ambient temperature and atmospheric pressure, for example aerosol propellants such as butane, propane, nitrogen and carbon dioxide. Tackifiers such as carboxymethylcellulose and natural and synthetic polymers in the form of powders, granules and latexes such as gum arabic, polyvinyl alcohol, polyvinyl acetate or other natural phospholipids such as cephalins and lecithins and synthetic phospholipids can be used in the formulations. Other possible additives are mineral and vegetable oils and waxes, optionally modified. If the filler used is water, it is also possible, for example, to use organic solvents as auxiliary solvents. Suitable liquid solvents are essentially: aromatic compounds such as xylene, toluene or alkyl naphthalenes, chlorinated aromatic compounds or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example mineral oil fractions, mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, highly polar solvents such as dimethylformamide and dimethyl sulfoxide, and water.

As used herein, the term "surfactant" includes an emulsifier, dispersing agent or wetting agent of the ionic or non-ionic type, or a mixture of such surfactants. Mention may be made, for example, of polyacrylic acid salts, lignosulfonic acid salts, phenolsulfonic or naphthalene sulfonic acid salts, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (in particular alkylphenols or arylphenols), salts of sulfosuccinic acid esters, taurine derivatives (in particular alkyl taurates), esters of phosphoric acid and polyoxyethylated alcohols or phenols, esters of fatty acids and polyhydric alcohols and derivatives of the above compounds containing sulfate, sulfonate and phosphate functional groups. The presence of at least one surfactant is generally necessary when the active compound and/or inert carrier are insoluble in water and when the vector agent to be used is water. Preferably, the surfactant content may range from 5 to 40% by weight of the composition.

Additional components may also be included, for example, protective colloids, adhesives, thickeners, thixotropic agents, penetrants, stabilizers, sequestrants. More generally, the active substances may be combined with any solid or liquid additive that follows conventional preparation techniques.

In addition, dyes such as inorganic pigments such as iron oxide, titanium oxide, Prussian blue, and organic dyes such as alizarin dyes, azo dyes and metallic phthalocyanine dyes, and trace elements such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.

In general, the compositions of the present invention may contain from 0.05 to 99% by weight of active substance, preferably from 0.1 to 95% by weight, more preferably from 1 to 90% by weight, most preferably from 10 to 70% by weight.

Compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, can be used in various forms, such as aerosol spray, capsule suspension, cold aerosol concentrate, spray powder, emulsifiable concentrate, oil in water emulsion, water in oil emulsion, encapsulated granules, fine granules, flowable seed treatment concentrate, gas (pressurized), gas generating product, granule, hot spray concentrate, macro granule, micro granule, oil dispersible powder, oil miscible flowable concentrate, oil miscible liquid, paste, plant core, dry seed treatment powder, pesticide coated seed, soluble concentrate, soluble powder, seed treatment solution, suspension concentrate (flowable concentrate), ultra low volume liquid ( ulv), ultra-low volume (ulv) suspension, water-dispersible granules or tablets, water-dispersible suspension treatment powder, water-soluble granules or tablets, water-soluble seed treatment powder and wettable powder.

These compositions include not only compositions that are ready to be applied to the plant or seed to be treated using a suitable device, such as a spray or pollination device, but also concentrated commercial compositions that must be diluted before application to the plant.

In one embodiment, compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, particularly fluopyram, and a fungicide selected from the group of phosphonates, particularly fosetyl aluminum, are sprayed onto the tree crown. In one embodiment, compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, are applied by spraying the shoots, trunks and leaves to be treated.

Application of compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, is expected to be carried out at an application rate of 0.1 to 1.5 kg/Ha/mCH of total active ingredient, preferably from 0.25 to 1 kg/ha/mCH. mCH stands for meter of crown height. In one embodiment, the application rate is 1 kg/Ha/mCH of total active ingredient; in another embodiment, the application rate is 0.666 kg/Ha/mCH of total active ingredient.

In one embodiment, the succinate dehydrogenase inhibitor application rate is from 0.01 to 0.5 or 0.05 to 0.8 kg/Ha/mCH, and the phosphonate application rate is from 0.05 to 0.8 kg/Ha/mCH . Preferably, the succinate dehydrogenase inhibitor application rate is from 0.03 to 0.4 kg/Ha/mCH, and the phosphonate application rate is from 0.2 to 0.7 kg/Ha/mCH.

In another embodiment, the application rate of fluopyram is from 0.01 to 0.5 kg/Ha/mCH, and the application rate of fosetyl aluminum is from 0.05 to 0.8 kg/Ha/mCH. Preferably, the application rate of fluopyram is from 0.03 to 0.4 kg/Ha/mCH, and the application rate of fosetyl aluminum is from 0.2 to 0.7 kg/Ha/mCH.

In another embodiment, the application rate of fluopyram is from 0.01 to 0.5 kg/Ha/mCH, preferably the application rate of fluopyram is from 0.03 to 0.4 kg/Ha/mCH, and the application rate of fosetyl aluminum is from 0.05 to 0.8 kg/Ha/mCH, Preferably, the fosetyl aluminum application rate is 0.2 to 0.7 kg/ha/mCH.

In another embodiment, the application rate of fosetyl aluminum is 0.666 kg/ha/mCH, and the application rate of fluopyram is 0.05 kg/ha/mCH. In another embodiment, the application rate of fosetyl aluminum is 0.444 kg/ha/mCH, and the application rate of fluopyram is 0.033 kg/ha/mCH.

In general, the weight ratio of succinate dehydrogenase inhibitor to phosphonate is between 2000:1 and 1:1000.

The weight ratio of succinate dehydrogenase inhibitor and phosphonate is preferably from 100:1 to 1:100; more preferably 20:1 to 1:50. The mixture of succinate dehydrogenase inhibitor and phosphonate active ingredients comprises a succinate dehydrogenase inhibitor and a phosphonate as described above, preferably in a ratio of 1000:1 to 1:1000, very preferably in a ratio of 50:1 to 1:50, more preferably in a ratio of 20:1 to 1 :20, even more preferably 10:1 to 1:10, very preferably 5:1 to 1:5, particularly preferred is a ratio of 2:1 to 1:2 and preferably a ratio of 4:1 25 to 2:1 , first of all the ratio is 1:1 or 5:1, or 5:2, or 5:3, or 5:4, or 4:1, or 4:2, or 4:3, or 3:1, or 3: 2, or 2: 1, or 1: 5, or 2: 5, or 3: 5, or 4: 5, or 1: 4, or 2: 4, or 3: 4, or 1: 3, or 2: 3, or 1:2, or 1:600, or 1:300, or 1:150, or 1:35, or 2:35, or 4:35, or 1:75, or 2:75, or 4: 75, or 1: 6000, or 1: 3000, or 1: 1500, or 1: 350, or 2: 350, or 4: 350, or 1: 750, or 2: 750, or 4: 750. It is clear that these mixing ratios include, on the one hand, mass ratios and, on the other hand, molar ratios.

In one embodiment, compositions containing a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, are applied by spraying the tree crown. In one embodiment, compositions containing fluopyram and fosetyl aluminum are applied by dipping, spraying, pollinating, irrigating, evaporating, painting, spreading, drenching, drip irrigation, applying fungicides with irrigation water, or injecting seedlings, root stems, grafted seedlings and cuttings, stems, shoots, trunks and leaves to be processed.

Application of compositions containing fluopyram and fosetyl aluminum is expected to be carried out preferably at an application rate of 0.15 to 2 kg/ha of active ingredient.

To convert kg of product per hectare of application to kg of product per Ha and meter of crown height (m CH), the following conversion can be applied: 3 kg of product per hectare of garden soil corresponds to 1 kg of product per m CH, or 2 kg per hectare of leaf wall area corresponds 1 kg of product per mCH.

In one embodiment, compositions containing fluopyram and fosetyl aluminum are applied up to three times per season after the BBCH 69 stage (post-flowering) to the pome fruit.

In one embodiment, compositions containing fluopyram and fosetyl aluminum are applied up to three times per season after the BBCH 69 stage (post-bloom) to apples.

In one embodiment, compositions containing fluopyram and fosetyl aluminum are applied up to three times per season after the BBCH 69 stage (post-bloom) to pears.

Compositions

Depending on their particular physical and/or chemical properties, a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram, and a fungicide selected from the group of phosphonates, in particular fosetyl aluminum, can be converted in accordance with the present invention into conventional formulations such as solutions, emulsions, suspensions, powders, foams, pastes, granules, sachets, aerosols, microencapsulations in polymeric substances and seed coating materials, and ULV compositions for irrigation with cold and hot aerosols.

The compositions contain, in general, from 0.01 to 95 wt. percentage of active ingredient, preferably from 0.05 to 90%, more preferably from 0.1 to 80%.

These compositions are prepared in a known manner, for example by mixing the active ingredients with excipients, i.e. liquid solvents, liquefied gases under pressure and/or solid carriers, optionally using surfactants, i.e. emulsifiers and/or dispersants and/or foaming agents. If water is used as a filler, it is possible, for example, to also use organic solvents as co-solvents. Liquid solvents which are suitable are generally: aromatic compounds such as xylene, toluene or alkyl naphthalenes, chlorinated aromatic or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example, mineral oil fractions, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, highly polar solvents such as dimethylformamide and dimethyl sulfoxide, and water, as well as mineral, animal and vegetable oils, such as, for example, palm oil or other plant seed oils. Liquefied gaseous expanders or carriers are understood to mean those liquids that are gaseous at normal temperature and pressure, for example, aerosol propellants such as halocarbons and butane, propane, nitrogen and carbon dioxide. Suitable solid carriers are: for example, ground natural minerals such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground synthetic minerals such as highly dispersed silica, alumina and silicates. Suitable solid carriers for granules are: for example, crushed and fractionated natural rocks such as calcite, pumice, marble, sepiolite, dolomite and synthetic granules from inorganic and organic ground products, and granules from organic material such as sawdust, shells coconut, corn cobs and tobacco leaf stalks. Emulsifiers and/or foaming agents that are suitable are: for example, nonionic, cationic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers, for example alkylaryl polyglycol ethers, alkyl sulfonates, alkyl sulfates, arylsulfonates and protein hydrolysates. Suitable dispersants are: for example, lignosulphite waste liquors and methylcellulose.

Tackifiers such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latexes such as gum acacia, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins, and synthetic phospholipids can be used in the compositions. Additional additives may be mineral and vegetable oils.

It is possible to use coloring agents such as inorganic pigments, for example iron oxide, titanium oxide, Prussian blue, and organic dyes such as alizarin, azo and metal phthalocyanine dyes, and trace elements such as salts of iron, manganese, boron, copper, cobalt , molybdenum and zinc.

One of the advantages of the present invention is that, due to the special systemic properties of fluopyram and fosetyl aluminum, the treatment of plants, plant parts, for example leaves, stems, trunks and shoots, as well as plants grown from seedlings, root shoots, grafted seedlings and cuttings, fluopyram and fosetyl aluminum not only fights mosaic rot on the plant itself, but also on parts of the plant that arise from it after the plant has grown. Thus, you can avoid immediately processing the crop before or during transplantation, or after.

The following examples serve to illustrate the present invention, but do not limit it.

Examples

Example 1 Mosaic rot on apple trees

Jonagold apple plants in apple orchards in Belgium were treated in different regimens with a variety of commercial standards, such as captan and dithianone, compared with formulations containing fluopyram and fosetyl aluminum in 2016 according to the application regimen outlined in Table 1.

The application volume was 300 L/Ha and fluopyram was applied at an application rate of 50 g/Ha/mCH, fosetyl aluminum was applied at an application rate of 666 g/Ha/mCH. This was consistent with Luna Care containing fluopyram and fosetyl aluminum up to an application rate of 1000g/ha/mCH.

Delan contains the active ingredient dithianon. Scala contains the active ingredient pyrimethanil. Geyser or Score contains the active ingredient difenoconazole. Flint plus contains the active ingredients trifloxystrobin and captan. Merpan contains the active ingredient captan. UTC corresponds to the raw control. Luna Privilege contains the active ingredient fluopyram. The raw control is abbreviated as UTC.

Table 1: Application data relative to phenological stages Dan-
new 04/12/2016 9DAB
04/21/2016 7DAB
04/28/2016 11DAC
09/05/2016 8DAD
05/17/2016 8DAF
02/06/2016 7DAG
09/06/2016 7DAH
16/06/2016 7DAI
06/23/2016 7DAJ
06/30/2016 BBCH 55 56 60 65 69 69 plus two weeks 72 73 75 77 Processing 1 UTC UTC Processing 2 Delan Merpan + Scala Merpan Merpan+Geyser Merpan Flint Plus Merpan Merpan Merpan Merpan Merpan Processing 3 LUNA CARE Merpan + Scala LUNA CARE Merpan+Geyser LUNA CARE Flint Plus Merpan Merpan Merpan Merpan Merpan Processing 4 Delan Merpan + Scala c Merpan Merpan+Geyser Merpan Flint Plus LUNA CARE Merpan LUNA CARE Merpan LUNA CARE

In Table 2, the incidence rate of mosaic blight was determined by evaluating 100 leaves. The standard regimen based on captan-dithianone is shown as treatment 2, in treatment 3 LUNA CARE is included in the primary period of classical scab when ascospores are released (from BBCH 55), and in treatment 4 a more recent regimen based on the use of LUNA CARE is disclosed. starting at BBCH 69 plus 2 weeks and lasting until BBCH 75, which covers the period when mosaic rot initially occurs. Statistical analysis was based on two-way Anova and multiple comparisons were based on the Newman-Keuls test. Student-Newman-Keuls test (P=0.05) was used for multiple comparisons of means and expressed by letters; processing lines that differ significantly are designated by different letters.

Table 2. Occurrence of Venturia inaequalis (%) with specific mosaic symptoms on the leaves of Jonagold apple trees at 4 time periods during the summer period

table 2 Evaluation data 06/29/2016 8/07/2016 07/18/2016 16/08/2016 Treatment Introductory Description AI-general FL-type Dosage form Processing codes average value average value average value average value 1 UNTREATED 35.3 a 40 a 50.5 a 83 a 2 DELAN
MERPAN
SCALA
MERPAN
MERPAN
SCORE
FLINT PLUS 75
80
400
80
80
250
64 W.P.
W.G.
S.C.
W.G.
W.G.
E.C.
W.G. 250 G/HA/M CH
600 G/HA/M CH
250 ML/HA/M CH
600 G/HA/M CH
600 G/HA/M CH
50 ML/HA/M CH
625 G/HA/M CH A
B
B
CEGHIJK
D
D
F 4.3 b 16 b 31 b 52.8 bc 3 LUNA CARE
MERPAN
SCALA
MERPAN
SCORE
FLINT PLUS
MERPAN 71.6
80
400
80
250
64
80 W.G.
W.G.
S.C.
W.G.
E.C.
W.G.
W.G. 1000 G/HA/M CH
600 G/HA/M CH
250 ML/GA/MCH
600 G/HA/M CH
50 ML/HA/MCH
625 G/HA/M CH
600 G/HA/M CH ACE
B
B
D
D
F
GHIJK 2.5 b 9.5 b 19.8 c 40.3 bc 4 DELAN
MERPAN
SCALA
MERPAN
MERPAN
SCORE
FLINT PLUS
LUNA CARE 75
80
400
80
80
250
64
71.6 W.P.
W.G.
S.C.
W.G.
W.G.
E.C.
W.G.
W.G. 250 G/HA/M CH
600 G/HA/M CH
250 ML/GA/MCH
600 G/HA/M CH
600 G/HA/M CH
50 ML/HA/MCH
625 G/HA/M CH
1000 G/HA/M CH A
B
B
C.E.H.J.
D
D
F
GIK 3.3 b 6 b 15.8 c 30.8 c

Example 2. Mosaic rot in apple trees

Jonagold apple plants in apple orchards in Belgium were treated in different regimens with a variety of commercial standards such as captan and dithianone compared to a formulation containing fluopyram and fosetyl aluminum in 2017 according to the application regimen outlined in Table 3.

The application volume was 300 L/Ha and fluopyram was applied at an application rate of 50 g/Ha/mCH, fosetyl aluminum was applied at an application rate of 666 g/Ha/mCH. This was consistent with Luna Care containing fluopyram and fosetyl aluminum up to an application rate of 1000g/ha/mCH.

Delan contains the active ingredient dithianon. Scala contains the active ingredient pyrimethanil. Geyser contains the active ingredient difenoconazole. Flint plus contains the active ingredients trifloxystrobin and captan. Merpan contains the active ingredient captan. UTC corresponds to the raw control. Luna Privilege contains the active ingredient fluopyram. The raw control is abbreviated as UTC.

Table 3 Apple tree code A B C D E F F* G H I J K date 05/04/2017 7DAA 12/04/2017 7DAB 04/19/2017 7DAC 04/26/2017 8DAD 05/3/2017 8DAE 12/05/2017 10DAF 22/05/2017 8DAF 05/30/2017 9DAG 8/06/
2017 11DAH
06/19/2017 9DAI 06/28/2017 12DAJ 10/07/
2017 BBCH 57 61-65 65 69 69 69 71 71 72 73 75 77 Processing 1 UTC Processing 2 Delan Merpan + Scala Merpan Merpan+Geyser Merpan Flint Plus Flint Plus Merpan Merpan Merpan Merpan Merpan Processing 3 Delan Merpan + Scala Merpan Merpan+Geyser Merpan Flint Plus Flint Plus LUNA CARE Merpan LUNA CARE Merpan LUNA CARE Processing 4 LUNA CARE Merpan + Scala LUNA CARE Merpan+Geyser LUNA CARE Flint Plus Flint Plus Merpan Merpan Merpan Merpan Merpan

The application volume is 300 l/Ha, and fluopyram is applied in an amount of 50 g/Ha/mCH, and fosetyl aluminum in an amount of 666 g/Ha/mCH. This corresponds to the finished product Luna Care with a dosage of 1000g/Ha/mCH.

Statistical analysis was based on two-way Anova and multiple comparisons were based on the Newman-Keuls test. Student-Newman-Keuls test (P=0.05) was used for multiple comparisons of means and expressed by letters; processing lines that differ significantly are designated by different letters.

Table 4 Incidence (%) of specific symptoms of mosaic rot on the leaves of Jonagold apple trees on September 4 at the BBCH 83 development stage.

Table 4 Evaluation data 4/09/2017 Treatment Introductory Description Dosage form Application codes Average (M) Treatment 1 UNTREATED 99 a Treatment 2 DELAN WG
MERPAN
SCALA
Flint Plus 0.05 KG/100L
1.9 Kg/Ha
0.75 L/ha
1.875 Kg/Ha A
BCDEGHIJK
B
F 57.4 b Treatment 3 DELAN WG
LUNA CARE
MERPAN
SCALA
Flint Plus 0.05 KG/100L
1 Kg/Ha/M CH
1.9 Kg/Ha
0.75 L/ha
1.875 Kg/Ha A
GIK
BCDEHJ
B
F 26.9 c Treatment 4 LUNA CARE
MERPAN
SCALA
Flint Plus 1 Kg/Ha/M CH
1.9 Kg/Ha
0.75 L/ha
1.875 Kg/Ha ACE
BDGHIJK
B
F 36.5 c

Example 3

Reducing Venturia inequalis inoculum

Apple cultivar Jonagold (Novajo mutation) apple plants in Belgium were treated with different regimens during the 2017 season according to a regimen based on different commercial standards such as captan and dithianone, pyrimethanil, difenconazole (versus a regimen comprising a composition comprising fluopyram and fosetyl aluminum in the early (BBCH 55 - BBCH 69) and late period in 2016 (BBCH 71 - BBCH 77) in accordance with the application scheme outlined in Table 5. From the treated areas and with four repetitions separately, all leaves dropped on soil, collected at 50 and 100% leaf shed, respectively, and stored together in plastic nets to avoid lateral impacts from neighboring areas.These captured leaves in the nets remained on the ground in the garden and were exposed to natural climatic conditions during the winter and spring of the following year. Ascospores released from formed pseudothecia in these leaves were captured by rotating rods at several time points (n = 18) during the main scab season from April 18 to July 4, 2017.

Table 5 Application code A B C D E F G H I J K date 04/12/2016 9DAB
04/21/2016 7DAB
04/28/2016 11DAC
09/05/2016 8DAD
05/17/2016 8DAF
05/25/2016 8DAG
02/06/
2016 7DAH
09/06/
2016 7DAI
16/06/
2016 7DAJ
23/06/
2016 Ascospores Ascospore peak Ascospores Ascospore peak Ascospores Conidia Conidia Conidia Conidia Conidia BBCH 55 56 60 65 69 71 72 73 75 77 Processing 1 UTC UTC Processing 2 Delan Merpan + pyrimethanil Merpan Merpan Merpan Flint Plus Merpan Merpan Merpan Merpan Merpan Processing 3 LUNA CARE Merpan + pyrimethanil LUNA CARE Merpan + difenconazole LUNA CARE Flint Plus Merpan Merpan Merpan Merpan Merpan Processing 4 Delan Merpan + pyrimethanil Merpan Merpan + difenconazole Merpan Flint Plus LUNA CARE Merpan LUNA CARE Merpan LUNA CARE

On rotating rod tapes with captured ascospores, the number of ascospores was determined using a quantitative PCR (qPCR) method that determines the DNA content of VENTURIA INEQUALIS in leaf material during the primary scab period. DNA extraction from apple leaves is carried out using a finely tuned qPCR method according to the methods of ILVO, Torfs S. et al. (in preparation for submission for publication). The amount of VENTURIA INEQUALIS DNA is expressed in spore equivalents as indicated in Table 6.

Table 6. Total number of ascospore equivalents detected by qPCR. Average number of ascospore equivalents detected significant difference Processing 1 examination 35763.542 a Processing 2 standard scheme 22858.292 Processing 3 early applications of Luna care 19408.446 Processing 4 late applications Luna care
Registered scheme 14633.898 b Processing 4 Smaller leaf symptom 851.78069 Processing 4 Leaves with mosaic rot only 21901.88

Pairwise comparisons of DUNCAN showed that Treatment 4 was significantly different from Treatment 1. Mosaic rot is added to the inoculum, out of 35,000 ascospore equivalents, for a total of about 22,000 ascospore equivalents associated with mosaic rot.

Example 4 Mosaic rot in apple trees

Novajo apple plants in apple orchards in Belgium were treated in different regimens with a variety of commercial standards such as captan and dithianone compared to a formulation containing fluopyram and fosetyl aluminum in 2017, according to the application regimen outlined in Table 7.

The application volume was 300 L/Ha and fluopyram was applied at an application rate of 50 g/Ha/mCH, fosetyl aluminum was applied at an application rate of 666 g/Ha/mCH. This was consistent with Luna Care containing fluopyram and fosetyl aluminum up to an application rate of 1000g/Ha/mCH.

Geyser contains the active ingredient difenoconazole. Flint plus contains the active ingredients trifloxystrobin and captan. Merpan contains the active ingredient captan. Scala contains the active ingredient pyrimethanil. Captan contains the active ingredient captan. UTC corresponds to the raw control. These products were used according to label directions.

Table 7 Treatment No. date UTC Standard scheme Fluopyram/Fosetil aluminum A 2016-04-12 N.A. Delan Delan B 2016-04-21 N.A. Captan + Scala Captan + Scala C 2016-04-28 N.A. Captain Captain D 2016-05-09 N.A. Captan+Geyser Captan+Geyser E 2016-05-17 N.A. Flint Plus Flint Plus F 2016-05-25 N.A. Captain Fluopyram + Fosetyl aluminum G 2016-06-02 N.A. Captain Captain H 2016-06-09 N.A. Captain Fluopyram + Fosetyl aluminum I 2016-06-16 N.A. Captain Captain J 2016-06-23 N.A. Captain Fluopyram + Fosetyl aluminum K 2016-06-30 N.A. Captain Fluopyram + Fosetyl aluminum

Efficacy against mosaic blight was measured as the incidence of new cases of Abbott 20 random rosette leaves in five cases. Abbott's incidence rate refers to the % reduction in the fungal population (see Abbott, J. Econ. Entomol. (125) 18:265-267). Therefore, the higher the number, the better the control of mosaic rot.

Date [days after processing no.] UTC Standard scheme Fluopyram/Fosetil aluminum 6 J 35.3 87.3 90.8 8K 40.0 60.0 85.0 18 K 50.5 38.6 68.8 47 K 83.0 36.4 63.0

Claims (4)

1. The use of a fungicidal composition containing fluopyram and fosetyl aluminum to combat the causative agent of apple tree disease Venturia inaequalis, which is applied at the stages of ascospore release and the stage of plant development starting from VSN 55 to VSN 75 at a consumption rate of 0.1 to 1.5 kg /Ha/mCH. 2. Application according to claim 1, characterized in that the composition is used at the stage of development of VSN 71. 3. Application according to claim 1, characterized in that the composition is applied at the development stage of VSN 69 plus two weeks. 4. Use of the composition according to any one of paragraphs. 1-3, characterized in that the composition reduces the amount of Venturia inequalis inoculum capable of infecting the plant or parts of the apple tree plant in the next season.